Minoxidil vs Finasteride: Which One Do You Need?

Two different approaches to the same problem

Minoxidil and finasteride are the two most established medical treatments for male pattern hair loss, but they work through completely different mechanisms. Understanding this difference is essential for choosing the right treatment, because the best choice depends on your specific hair loss pattern, stage, tolerance for medication, and long-term goals.

Finasteride is a systemic oral medication (pill) that blocks the enzyme responsible for converting testosterone to DHT. By reducing DHT levels by 60 to 70%, it addresses the hormonal root cause of androgenetic alopecia. It primarily prevents further hair loss and can promote regrowth of miniaturized follicles.

Minoxidil is a topical treatment (liquid or foam) applied directly to the scalp. It was originally developed as a blood pressure medication, and its hair growth effects were discovered as a side effect. It works by increasing blood flow to hair follicles and extending the growth phase (anagen) of the hair cycle. It does not affect DHT levels.

Effectiveness comparison

Head-to-head data consistently favors finasteride as the more effective standalone treatment. In studies comparing the two, finasteride produces greater improvements in hair count and patient satisfaction. Finasteride maintains or improves hair in 83 to 90% of men over 2 years, while topical minoxidil 5% shows meaningful improvement in approximately 40 to 60% of users.

However, direct comparisons have limitations. Finasteride's effects are primarily on the vertex (crown) and mid-scalp, with moderate effects on the frontal hairline. Minoxidil can be applied anywhere on the scalp and may provide some benefit in areas where finasteride is less effective. The two treatments also have different response timelines: minoxidil can show early effects at 2 to 3 months, while finasteride typically takes 6 to 12 months for visible results.

The most important insight from clinical data is that combination therapy outperforms either treatment alone. A study in Dermatologic Therapy found that patients using both finasteride and minoxidil had significantly greater hair density improvement than those using either medication individually. This is why most dermatologists and hair loss specialists recommend starting with both if the patient is a candidate.

Who should use which treatment

Finasteride alone may be sufficient for men with early-stage hair loss (Norwood 2 to 3) who primarily want to prevent further loss. It is also preferred by patients who want a simple daily pill rather than a topical application routine. Patients with crown thinning tend to respond particularly well to finasteride.

Minoxidil alone is appropriate for men who cannot or prefer not to take finasteride due to side effect concerns, women with pattern hair loss (finasteride is not approved for women), or patients with localized thinning who want targeted topical treatment. It is also useful as a first-line treatment for patients who want to start conservatively and add finasteride later if needed.

Combination therapy is recommended for men with moderate to advanced hair loss (Norwood 3 to 5), those who want maximum results, and patients who have used one treatment alone with incomplete response. Providers like Hims, Ro, and Keeps all offer combination treatment options through their platforms.

Side effects compared

Finasteride side effects are systemic because it is taken orally. Sexual side effects (decreased libido, erectile changes, reduced ejaculate volume) occur in approximately 2 to 4% of men in clinical trials. These effects are usually reversible upon discontinuation. Topical finasteride formulations are emerging as an alternative with potentially lower systemic exposure, though long-term data is still limited.

Minoxidil side effects are primarily local. Scalp irritation, dryness, flaking, and contact dermatitis are the most common. The propylene glycol in liquid minoxidil formulations is a frequent cause of irritation; foam formulations without propylene glycol are often better tolerated. Systemic absorption is minimal with topical use, but some patients report lightheadedness or increased heart rate, particularly with higher concentrations.

Both treatments can cause an initial 'shedding phase' in the first 1 to 3 months as weakened hairs are displaced by new growth. This is temporary and is actually a positive indicator of treatment response, but it can be distressing if patients are not warned in advance.

This guide is educational and not a substitute for personal medical advice. Eligibility, contraindications, and monitoring needs differ across individuals, which is why treatment decisions should be reviewed with a licensed clinician.